INBSHealthcare · Medical Devices

INBS Stock Forecast: Intelligent Bio Solutions, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$2.48

−6.42% on the day

The 1 Wall Street analysts covering Intelligent Bio Solutions, Inc. hold a median 12-month price target of $12 — +383.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$7.6M

Ticker Nerd rank

9 / 100

Median analyst target

$12

Analysts covering

Total return, dividends reinvested

−10.5%

+37.0%

YTD

−74.0%

−83.1%

From 52W high

−86.8%

From 52W low

+60.0%

$19

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

INBS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Intelligent Bio Solutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

9 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Growth

Accruals

Value

Quality

Volatility

Issuance

Momentum

Size (94): Smaller than most of the companies we track.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INBS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INBS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $12Median $12High $12

The green dot is the last close — the median target sits +383.9% from it.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INBS appears on the weeks it earns a place.

Estimates

INBS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Intelligent Bio Solutions, Inc. (INBS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 10.1×
Price / sales: 1.8×
Price / book: 0.6×
EV / EBITDA: −0.5×

Growth & margins

Revenue growth (YoY): 35.8%
Earnings growth (YoY): 45.5%
Gross margin: 50.5%
Operating margin: −346.0%
Net margin: −294.9%

Returns & dividend

Return on equity: −307.7%
Return on assets: −76.2%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

INBS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
INBSIntelligent Bio Solutions, Inc.	$7.6M	9
CODXCo-Diagnostics, Inc.	$7.6M	37
PMIPicard Medical, Inc.	$7.5M	33
NXLNexalin Technology, Inc.	$7.3M	38
ICCMIceCure Medical Ltd.	$6.8M	38
AIDX20/20 Biolabs, Inc.	$6.8M	5
NVNOenVVeno Medical Corp.	$6.7M	33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Intelligent Bio Solutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INBS news & analysis

Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth

GlobeNewsWire · 19 Aug 2026positive

Intelligent Bio Solutions, Inc. reported fiscal 2026 full-year revenue growth of 38% year-over-year, driven by a 22% growth in its reader installed base and a 35% increase in total consumable cartridges to over 100,000 units, which the company attributes to high-margin cartridge growth.

Why it matters — The 38% annual revenue growth, driven by an expanding installed base and rising high-margin cartridge sales, indicates strengthening recurring revenue from Intelligent Bio Solutions' core diagnostic reader business.

Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action?

Benzinga · 17 Aug 2026positive

Intelligent Bio Solutions Inc. shares surged Monday afternoon after the medical technology company announced a significant regulatory milestone for its rapid testing unit. The announcement drove the stock's upward movement.

Why it matters — A regulatory milestone for the rapid testing unit is a notable development for INBS watchers because it could affect the company's testing business prospects.

Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification

GlobeNewsWire · 17 Aug 2026positive

Intelligent Bio Solutions has been recertified under ISO standards, aligning its quality management system with the FDA's newly amended Quality Management System Regulation. The recertification supports the Company's regulatory strategy as it pursues FDA clearance.

Why it matters — For INBS watchers, this ISO recertification marks progress in the Company's quality management credentials and regulatory preparation as it advances toward FDA clearance.

Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission

GlobeNewsWire · 5 Aug 2026positive

Intelligent Bio Solutions completed a Usability Study for its Intelligent Fingerprinting Drug Screening System, conducted with CenExel Clinical Research in line with FDA guidance, to support the Company's 510(k) submission seeking U.S. market clearance for detection of the opiate codeine.

Why it matters — This milestone moves INBS closer to potential FDA clearance and U.S. market entry for its fingerprint-based drug screening technology.

Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System

GlobeNewsWire · 3 Aug 2026positive

Intelligent Bio Solutions announced the completion of its Interference Study for the Intelligent Fingerprinting Drug Screening System. The study evaluates the impact of everyday substances and supports the Company's FDA 510(k) submission seeking U.S. market clearance for detection of the opiate codeine.

Why it matters — Completion of this study marks progress in INBS's regulatory efforts toward potential U.S. clearance of its fingerprint-based drug screening system.

FAQ

Frequently asked questions about INBS stock

What is the INBS stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Intelligent Bio Solutions, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INBS stock a buy right now?

Of the 1 analysts covering Intelligent Bio Solutions, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Intelligent Bio Solutions, Inc. 9 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INBS?

As at 22 Aug 2026, Intelligent Bio Solutions, Inc. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will INBS stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +383.9% from the last close, and Ticker Nerd's factor model ranks Intelligent Bio Solutions, Inc. 9 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INBS stock forecast for 2030?

No analyst covering Intelligent Bio Solutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INBS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has INBS stock performed over the past year?

Intelligent Bio Solutions, Inc. returned -83.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Intelligent Bio Solutions, Inc. do?

Intelligent Bio Solutions Inc. is a medical technology company specializing in intelligent, rapid, non-invasive testing solutions.

What is the latest news on INBS?

The most recent item we track (GlobeNewsWire, 19 Aug 2026): "Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth". Intelligent Bio Solutions, Inc. reported fiscal 2026 full-year revenue growth of 38% year-over-year, driven by a 22% growth in its reader installed base and a 35% increase in total consumable cartridges to over 100,000 units, which the company attributes to high-margin cartridge growth.

Company

About Intelligent Bio Solutions, Inc.

Intelligent Bio Solutions Inc. is a medical technology company specializing in intelligent, rapid, non-invasive testing solutions. Its primary offering, the Intelligent Fingerprinting Drug Testing Solution, utilizes fingerprint sweat analysis to detect recent use of common workplace drugs such as opiates, cocaine, methamphetamine, cannabis, benzodiazepines, and marijuana. This portable, hygienic, and cost-effective system enables sample collection in seconds and delivers results in under ten minutes, making it ideal for safety-critical environments. The company serves diverse industries including construction, mining, manufacturing, engineering, transport, logistics, drug treatment, law enforcement, and forensics, with accounts spanning multiple countries. Additionally, Intelligent Bio Solutions Inc. develops a Saliva Glucose Biosensor Platform aimed at real-time monitoring and diagnostic tests for chronic disease management. Operating through segments like Intelligent Fingerprinting Products and the biosensor platform, it focuses on advancing portable drug screening and biosensor technologies across regions including the United Kingdom, Asia Pacific, Americas, and rest of world. Founded in 2016 and headquartered in New York, New York, the company plays a key role in the growing market for non-invasive medical diagnostics.

CEO Mr. Harry Simeonidis · 53 employees · United States · https://ibs.inc